Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial

Mai, E. K., Nogai, A., Lokhorst, H. M., van der Holt, B., Zweegman, S., Weisel, K. C., … Sonneveld, P. (2024, November 1). Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial. HemaSphere. John Wiley and Sons Inc. https://doi.org/10.1002/hem3.70052